Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- INM
- Price
- 2.74
- Stock movement up
- +0.21 (8.29%)
- Company name
- InMed Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.97M
- Ent value
- 2.07B
- Price/Sales
- 0.40
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -53.90%
- 1 year return
- 640.54%
- 3 year return
- -50.17%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.40 |
| Price to Book | - |
| EV to Sales | 416.50 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 718.08K |
| EPS (TTM) | -2.71 |
| FCF per share (TTM) | -2.95 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 4.96M |
| Gross profit (TTM) | -6.99B |
| Operating income (TTM) | -9.61B |
| Net income (TTM) | -1.68B |
| EPS (TTM) | -2.71 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -140868.22% |
| Operating margin (TTM) | -193769.62% |
| Profit margin (TTM) | -33928.13% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.58M |
| Net receivables | 284.69M |
| Total current assets | 7.28B |
| Goodwill | 1.74B |
| Intangible assets | 1.74M |
| Property, plant and equipment | 0.00 |
| Total assets | 10.47M |
| Accounts payable | 449.00K |
| Short/Current long term debt | 1.06M |
| Total current liabilities | 1.44B |
| Total liabilities | 2.07B |
| Shareholder's equity | -2.06B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -1.83B |
| Capital expenditures (TTM) | 18.58K |
| Free cash flow (TTM) | -1.83B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -16082.08% |
| Return on Invested Capital | 81.75% |
| Cash Return on Invested Capital | 88.97% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.62 |
| Daily high | 2.85 |
| Daily low | 2.51 |
| Daily Volume | 221K |
| All-time high | 220.00 |
| 1y analyst estimate | 20.00 |
| Beta | 0.71 |
| EPS (TTM) | -2.71 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| INM | S&P500 | |
| Current price drop from All-time high | -98.75% | -12.89% |
| Highest price drop | -99.94% | -56.47% |
| Date of highest drop | 6 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -82.39% | -11.07% |
| Avg time to new high | 123 days | 12 days |
| Max time to new high | 653 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.97M
Marketcap category
Small-cap
Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page